Literature DB >> 28027817

Management of endoscopic retrograde cholangiopancreatography-related perforations: Experience of a tertiary center.

Roi Weiser1, Niv Pencovich2, Liat Mlynarsky3, Adi Berliner-Senderey4, Guy Lahat2, Erwin Santo3, Joseph M Klausner2, Ido Nachmany2.   

Abstract

BACKGROUND: Endoscopic retrograde cholangiopancreatography-induced perforation (EP) is a rare but severe complication. We describe the risk factors, management, and outcome of ERCP-induced perforations in a tertiary center.
METHODS: This is a case-control study. All EP cases between March 2004 and February 2015 were compared to a control group without perforation. Data on patients, procedures, presentation, perforation type, radiologic findings, management, and outcome were assessed.
RESULTS: Of 6,934 endoscopic retrograde cholangiopancreatographies, 37 patients (0.53%) had EP. Independent risk factors included failure of cannulation, a procedure described as "difficult," performing a precut and resection of a periampullary adenoma. Perforation was diagnosed during the procedure in 7 patients (19%). Median interval for diagnosis was 11 hours (range: 0-201 hours), with 84% diagnosed within 30 hours. The periampullary region was the most common EP site (51%). Twenty-nine patients (78%) were managed conservatively and 8 (22%) were operated. Three patients failed conservative management and required delayed operation. Failure of conservative management had a detrimental effect on morbidity and duration of stay. All patients who required operative intervention had perforation of either the duodenal free wall or the periampullary region.
CONCLUSION: Clear risk factors can be used to raise suspicion of EP. Early diagnosis and management are critical for better outcome. This is especially important when operative intervention is indicated. Nonetheless, the majority of patients may be managed conservatively.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28027817     DOI: 10.1016/j.surg.2016.10.029

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  5 in total

1.  Surgical Treatment for Choledocholithiasis Following Repeated Failed Endoscopic Retrograde Cholangiopancreatography.

Authors:  Muhammad Younis; Niv Pencovich; Reut El-On; Nir Lubezky; Yaacov Goykhman; Adam Phillips; Ido Nachmany
Journal:  J Gastrointest Surg       Date:  2022-03-30       Impact factor: 3.267

2.  Difficult Biliary Cannulation in Endoscopic Retrograde Cholangiopancreatography: Definitions, Risk Factors, and Implications.

Authors:  Brian M Fung; Teodor C Pitea; James H Tabibian
Journal:  Eur Med J Hepatol       Date:  2021-08-05

Review 3.  Recent advances in prevention and management of endoscopic retrograde cholangiopancreatography-related duodenal perforation.

Authors:  Guiying Zhu; Fenglin Hu; Changmiao Wang
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-11-18       Impact factor: 1.195

4.  Surgical versus non-operative initial management of post-endoscopic retrograde cholangiopancreatography perforation: a systematic review and meta-analysis.

Authors:  Athina A Samara; Alexandros Diamantis; Konstantinos Perivoliotis; Georgios Mavrovounis; Dimitrios Symeonidis; Ioannis Baloyiannis; Dimitris Zacharoulis
Journal:  Ann Gastroenterol       Date:  2021-10-12

Review 5.  Duodeno-pancreatic and extrahepatic biliary tree trauma: WSES-AAST guidelines.

Authors:  Federico Coccolini; Leslie Kobayashi; Yoram Kluger; Ernest E Moore; Luca Ansaloni; Walt Biffl; Ari Leppaniemi; Goran Augustin; Viktor Reva; Imitiaz Wani; Andrew Kirkpatrick; Fikri Abu-Zidan; Enrico Cicuttin; Gustavo Pereira Fraga; Carlos Ordonez; Emmanuil Pikoulis; Maria Grazia Sibilla; Ron Maier; Yosuke Matsumura; Peter T Masiakos; Vladimir Khokha; Alain Chichom Mefire; Rao Ivatury; Francesco Favi; Vassil Manchev; Massimo Sartelli; Fernando Machado; Junichi Matsumoto; Massimo Chiarugi; Catherine Arvieux; Fausto Catena; Raul Coimbra
Journal:  World J Emerg Surg       Date:  2019-12-11       Impact factor: 5.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.